Viela Bio

Investors/Media

Press Releases

Press Releases

2.25.2021
Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum
-No new safety signals were identified with prolonged inebilizumab treatment and  inebilizumab-mediated B-cell depletion- -UPLIZNA was shown to be safe and effective in patients with  previous exposure to off-label therapy- GAITHERSBURG, Md. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Viela Bio 
2.22.2021
Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021
GAITHERSBURG, Md. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viela Bio  (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today announced it will report its fourth

Shareholder Tools